What should a cardiologist know about coronavirus disease 2019?
Identifieur interne : 000030 ( Main/Exploration ); précédent : 000029; suivant : 000031What should a cardiologist know about coronavirus disease 2019?
Auteurs : Grzegorz Sławi Ski ; Ewa LewickaSource :
- Kardiologia polska [ 1897-4279 ] ; 2020.
Descripteurs français
- KwdFr :
- Antagonistes des récepteurs aux angiotensines (effets indésirables), Antagonistes des récepteurs aux angiotensines (usage thérapeutique), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Cardiologie (MeSH), Comorbidité (MeSH), Coûts indirects de la maladie (MeSH), Diabète (épidémiologie), Humains (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (métabolisme), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (épidémiologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables), Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique), Maladies cardiovasculaires (traitement médicamenteux), Maladies cardiovasculaires (épidémiologie), Maladies cardiovasculaires (étiologie), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (diagnostic), Pneumopathie virale (métabolisme), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (épidémiologie), Pratique professionnelle (MeSH), Pronostic (MeSH), Soins de réanimation (MeSH), Tomodensitométrie (MeSH).
- MESH :
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- effets indésirables : Antagonistes des récepteurs aux angiotensines, Antiviraux, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- métabolisme : Infections à coronavirus, Peptidyl-Dipeptidase A, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- usage thérapeutique : Antagonistes des récepteurs aux angiotensines, Antiviraux, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- épidémiologie : Diabète, Infections à coronavirus, Maladies cardiovasculaires, Pneumopathie virale.
- étiologie : Maladies cardiovasculaires.
- Cardiologie, Comorbidité, Coûts indirects de la maladie, Humains, Pandémies, Pratique professionnelle, Pronostic, Soins de réanimation, Tomodensitométrie.
English descriptors
- KwdEn :
- Angiotensin Receptor Antagonists (adverse effects), Angiotensin Receptor Antagonists (therapeutic use), Angiotensin-Converting Enzyme Inhibitors (adverse effects), Angiotensin-Converting Enzyme Inhibitors (therapeutic use), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Cardiology (MeSH), Cardiovascular Diseases (drug therapy), Cardiovascular Diseases (epidemiology), Cardiovascular Diseases (etiology), Comorbidity (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (metabolism), Cost of Illness (MeSH), Critical Care (MeSH), Diabetes Mellitus (epidemiology), Humans (MeSH), Pandemics (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (diagnosis), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (metabolism), Professional Practice (MeSH), Prognosis (MeSH), Tomography, X-Ray Computed (MeSH).
- MESH :
- chemical , adverse effects : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antiviral Agents.
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , therapeutic use : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Antiviral Agents.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Cardiovascular Diseases, Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Cardiovascular Diseases, Coronavirus Infections, Diabetes Mellitus, Pneumonia, Viral.
- etiology : Cardiovascular Diseases.
- metabolism : Coronavirus Infections, Pneumonia, Viral.
- Cardiology, Comorbidity, Cost of Illness, Critical Care, Humans, Pandemics, Professional Practice, Prognosis, Tomography, X-Ray Computed.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the cause of coronavirus disease 2019 (COVID‑19). The most common symptoms of COVID‑19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID‑19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C‑reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D‑dimer concentrations (36%-46.4%). Among comorbidities in patients with COVID‑19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID‑19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID‑19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N‑terminal pro-B‑type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life‑threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID‑19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID‑19 symptoms, possible clinical manifestations, complications, and recommended treatment.
DOI: 10.33963/KP.15302
PubMed: 32336069
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What should a cardiologist know about coronavirus disease 2019?</title><author><name sortKey="Slawi Ski, Grzegorz" sort="Slawi Ski, Grzegorz" uniqKey="Slawi Ski G" first="Grzegorz" last="Sławi Ski">Grzegorz Sławi Ski</name></author><author><name sortKey="Lewicka, Ewa" sort="Lewicka, Ewa" uniqKey="Lewicka E" first="Ewa" last="Lewicka">Ewa Lewicka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32336069</idno><idno type="pmid">32336069</idno><idno type="doi">10.33963/KP.15302</idno><idno type="wicri:Area/Main/Corpus">000338</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000338</idno><idno type="wicri:Area/Main/Curation">000338</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000338</idno><idno type="wicri:Area/Main/Exploration">000338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">What should a cardiologist know about coronavirus disease 2019?</title><author><name sortKey="Slawi Ski, Grzegorz" sort="Slawi Ski, Grzegorz" uniqKey="Slawi Ski G" first="Grzegorz" last="Sławi Ski">Grzegorz Sławi Ski</name></author><author><name sortKey="Lewicka, Ewa" sort="Lewicka, Ewa" uniqKey="Lewicka E" first="Ewa" last="Lewicka">Ewa Lewicka</name></author></analytic><series><title level="j">Kardiologia polska</title><idno type="eISSN">1897-4279</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (adverse effects)</term><term>Angiotensin Receptor Antagonists (therapeutic use)</term><term>Angiotensin-Converting Enzyme Inhibitors (adverse effects)</term><term>Angiotensin-Converting Enzyme Inhibitors (therapeutic use)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Cardiology (MeSH)</term><term>Cardiovascular Diseases (drug therapy)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Cardiovascular Diseases (etiology)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (metabolism)</term><term>Cost of Illness (MeSH)</term><term>Critical Care (MeSH)</term><term>Diabetes Mellitus (epidemiology)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (metabolism)</term><term>Professional Practice (MeSH)</term><term>Prognosis (MeSH)</term><term>Tomography, X-Ray Computed (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (effets indésirables)</term><term>Antagonistes des récepteurs aux angiotensines (usage thérapeutique)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Cardiologie (MeSH)</term><term>Comorbidité (MeSH)</term><term>Coûts indirects de la maladie (MeSH)</term><term>Diabète (épidémiologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (métabolisme)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (épidémiologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (usage thérapeutique)</term><term>Maladies cardiovasculaires (traitement médicamenteux)</term><term>Maladies cardiovasculaires (épidémiologie)</term><term>Maladies cardiovasculaires (étiologie)</term><term>Pandémies (MeSH)</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (métabolisme)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (épidémiologie)</term><term>Pratique professionnelle (MeSH)</term><term>Pronostic (MeSH)</term><term>Soins de réanimation (MeSH)</term><term>Tomodensitométrie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Antiviraux</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Coronavirus Infections</term><term>Diabetes Mellitus</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Peptidyl-Dipeptidase A</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Antiviraux</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Diabète</term><term>Infections à coronavirus</term><term>Maladies cardiovasculaires</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cardiology</term><term>Comorbidity</term><term>Cost of Illness</term><term>Critical Care</term><term>Humans</term><term>Pandemics</term><term>Professional Practice</term><term>Prognosis</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cardiologie</term><term>Comorbidité</term><term>Coûts indirects de la maladie</term><term>Humains</term><term>Pandémies</term><term>Pratique professionnelle</term><term>Pronostic</term><term>Soins de réanimation</term><term>Tomodensitométrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the cause of coronavirus disease 2019 (COVID‑19). The most common symptoms of COVID‑19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID‑19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C‑reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D‑dimer concentrations (36%-46.4%). Among comorbidities in patients with COVID‑19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID‑19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID‑19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N‑terminal pro-B‑type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life‑threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID‑19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID‑19 symptoms, possible clinical manifestations, complications, and recommended treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32336069</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1897-4279</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>24</Day></PubDate></JournalIssue><Title>Kardiologia polska</Title><ISOAbbreviation>Kardiol Pol</ISOAbbreviation></Journal><ArticleTitle>What should a cardiologist know about coronavirus disease 2019?</ArticleTitle><Pagination><MedlinePgn>278-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.33963/KP.15302</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is the cause of coronavirus disease 2019 (COVID‑19). The most common symptoms of COVID‑19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID‑19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum C‑reactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and D‑dimer concentrations (36%-46.4%). Among comorbidities in patients with COVID‑19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID‑19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID‑19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated N‑terminal pro-B‑type natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the life‑threatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID‑19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID‑19 symptoms, possible clinical manifestations, complications, and recommended treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sławiński</LastName><ForeName>Grzegorz</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lewicka</LastName><ForeName>Ewa</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Kardiol Pol</MedlineTA><NlmUniqueID>0376352</NlmUniqueID><ISSNLinking>0022-9032</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002309" MajorTopicYN="N">Cardiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011364" MajorTopicYN="N">Professional Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32336069</ArticleId><ArticleId IdType="doi">10.33963/KP.15302</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Lewicka, Ewa" sort="Lewicka, Ewa" uniqKey="Lewicka E" first="Ewa" last="Lewicka">Ewa Lewicka</name><name sortKey="Slawi Ski, Grzegorz" sort="Slawi Ski, Grzegorz" uniqKey="Slawi Ski G" first="Grzegorz" last="Sławi Ski">Grzegorz Sławi Ski</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000030 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000030 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32336069
|texte= What should a cardiologist know about coronavirus disease 2019?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32336069" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |